Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines

SIMPLE SUMMARY: Melanoma is the most aggressive, deadliest form of skin cancer. Combined BRAF-MEK inhibitor (BRAFi/MEKi) therapy was a breakthrough in the treatment of melanoma with BRAFV600-mutations. However, many patients frequently develop drug resistance to the combinatory treatment. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Vikas, Szász, István, Koroknai, Viktória, Kiss, Tímea, Balázs, Margit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656772/
https://www.ncbi.nlm.nih.gov/pubmed/34885166
http://dx.doi.org/10.3390/cancers13236058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656772/
https://www.ncbi.nlm.nih.gov/pubmed/34885166
http://dx.doi.org/10.3390/cancers13236058

Ejemplares similares